Clinical Trial Update: Vyxeos for Induction of Low- or Intermediate-risk. [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 study of Vyxeos (CPX-351) as induction therapy for adults with acute myeloid leukemia at low- or intermediate-risk; the trial i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Vyxeos (CPX-351)

Snippet

Sponsor: Shaare Zedek Medical Center | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: ACTIVE_NOT_RECRUITING